Coversyl Plus Contraindications

Linked to perindopril: Hypersensitivity to the active substance or to any other ACE inhibitor; History of angioedema (Quincke's oedema) associated with previous ACE inhibitor therapy (see Warnings); Hereditary/idiopathic angioedema; Second and third trimesters of pregnancy (see Warnings and Use in Pregnancy & Lactation); Concomitant use of Coversyl Plus 5mg/1.25 mg and 10mg/2.5 mg with aliskiren-containing products in patients with diabetes mellitus or renal impairment (GFR < 60 ml/min/1.73 m²) (see Interactions and Pharmacology: Pharmacodynamics under Actions); Concomitant use with sacubitril/valsartan (see Warnings and Interactions); Extracorporeal treatments leading to contact of blood with negatively charged surfaces (see Interactions); Significant bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney (see Warnings and Precautions).
Linked to indapamide: Hypersensitivity to the active substance or to any other sulphonamides; Hepatic encephalopathy; Severe hepatic impairment; Hypokalaemia; As a general rule, this medicine is inadvisable in combination with non antiarrhythmic agents causing torsades de pointes (see Interactions); Lactation (see Use in Pregnancy & Lactation).
5 mg/1.25 mg Tablet: Severe renal impairment (creatinine clearance below 30 ml/min).
10 mg/2.5 mg Tablet: Severe and moderate renal impairment (creatinine clearance below 60 ml/min).
Linked to Coversyl Plus 5mg/1.25 mg and 10mg/2.5 mg: Hypersensitivity to any of the excipients listed in Description.
Due to the lack of sufficient therapeutic experience, Coversyl Plus should not be used in: Dialysis patients; Patients with untreated decompensated heart failure.